• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GLP-1 receptor agonists in lean diabetes in racial and ethnic minority groups: closing the treatment gap.

作者信息

Chilunga Felix P, Mkoma George F

机构信息

Department of Public and Occupational Health, Amsterdam Public Health Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.

出版信息

Diabetologia. 2024 Dec;67(12):2833-2835. doi: 10.1007/s00125-024-06297-z. Epub 2024 Oct 21.

DOI:10.1007/s00125-024-06297-z
PMID:39432078
Abstract
摘要

相似文献

1
GLP-1 receptor agonists in lean diabetes in racial and ethnic minority groups: closing the treatment gap.种族和少数族裔群体中瘦型糖尿病患者使用胰高血糖素样肽-1受体激动剂：缩小治疗差距
Diabetologia. 2024 Dec;67(12):2833-2835. doi: 10.1007/s00125-024-06297-z. Epub 2024 Oct 21.
2
The diabetes cardiovascular outcomes trials and racial and ethnic minority enrollment: impact, barriers, and potential solutions.糖尿病心血管结局试验与种族和少数民族入组：影响、障碍和潜在解决方案。
Front Public Health. 2024 Oct 25;12:1412874. doi: 10.3389/fpubh.2024.1412874. eCollection 2024.
3
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效：综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
4
Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis.胰高血糖素样肽-1受体激动剂试验中主要心血管事件的种族/民族和地理差异：一项荟萃分析。
Curr Probl Cardiol. 2023 Nov;48(11):101940. doi: 10.1016/j.cpcardiol.2023.101940. Epub 2023 Jul 7.
5
Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.在美国退伍军人事务部医疗体系中，2 型糖尿病患者种族和民族与 SGLT2 抑制剂和 GLP1 受体激动剂处方的相关性。
JAMA. 2022 Sep 6;328(9):861-871. doi: 10.1001/jama.2022.13885.
6
Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?胰高血糖素样肽-1 在糖尿病治疗中的作用：能否在不引起恶心和呕吐的情况下实现血糖控制？
Br J Pharmacol. 2022 Feb;179(4):542-556. doi: 10.1111/bph.15647. Epub 2021 Sep 14.
7
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.2型糖尿病患者中SGLT2抑制剂和GLP-1受体激动剂的种族、民族与药房配药情况
Lancet Reg Health Am. 2024 May 7;34:100759. doi: 10.1016/j.lana.2024.100759. eCollection 2024 Jun.
8
Closing the Gap in Hospice Utilization for the Minority Medicare Population.缩小少数族裔医疗保险人群临终关怀服务利用方面的差距。
Gerontol Geriatr Med. 2019 Jun 27;5:2333721419855667. doi: 10.1177/2333721419855667. eCollection 2019 Jan-Dec.
9
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂和协同激动剂对身体成分的影响：系统评价与网状荟萃分析。
Metabolism. 2025 Mar;164:156113. doi: 10.1016/j.metabol.2024.156113. Epub 2024 Dec 22.
10
Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey.波士顿地区社区健康调查中2型糖尿病治疗模式和血糖控制的种族差异
BMJ Open. 2015 May 12;5(5):e007375. doi: 10.1136/bmjopen-2014-007375.

本文引用的文献

1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
2
Incretin hormones and type 2 diabetes.肠促胰岛素激素与 2 型糖尿病。
Diabetologia. 2023 Oct;66(10):1780-1795. doi: 10.1007/s00125-023-05956-x. Epub 2023 Jul 11.
3
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
2022 年美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的共识报告：2 型糖尿病患者高血糖管理。
Diabetologia. 2022 Dec;65(12):1925-1966. doi: 10.1007/s00125-022-05787-2. Epub 2022 Sep 24.
4
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.每周一次司美格鲁肽 2.0 mg 与 1.0 mg 治疗 2 型糖尿病患者的疗效和安全性（SUSTAIN FORTE）：一项双盲、随机、3B 期临床试验。
Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1. Epub 2021 Jul 21.
5
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study.基于英国 2 型糖尿病风险的种族特异性 BMI 切点与肥胖：一项基于人群的队列研究。
Lancet Diabetes Endocrinol. 2021 Jul;9(7):419-426. doi: 10.1016/S2213-8587(21)00088-7. Epub 2021 May 11.
6
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.皮下司美格鲁肽与安慰剂作为强化行为疗法辅助手段对超重或肥胖成人体重的影响：STEP 3 随机临床试验。
JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
7
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.SUSTAIN China 研究：每周一次司美格鲁肽对比每日一次西格列汀作为二甲双胍添加治疗在中国 2 型糖尿病患者中的疗效和安全性：一项 30 周、双盲、3a 期、随机临床试验。
Diabetes Obes Metab. 2021 Feb;23(2):404-414. doi: 10.1111/dom.14232. Epub 2021 Jan 3.
8
Prevalence and determinants of type 2 diabetes among lean African migrants and non-migrants: the RODAM study.瘦型非洲移民与非移民 2 型糖尿病的患病率及其决定因素：RODAM 研究。
J Glob Health. 2019 Dec;9(2):020426. doi: 10.7189/jogh.09.020426.
9
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.在治疗 2 型糖尿病方面，每周一次皮下注射司美格鲁肽的疗效、安全性和心血管结局比较：来自 SUSTAIN 1-7 试验的结果。
Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4.
10
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.